Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;15(9):1218-1228.
doi: 10.1016/j.jalz.2019.04.011. Epub 2019 Aug 6.

Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome

Affiliations

Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome

Nobutaka Sakae et al. Alzheimers Dement. 2019 Sep.

Abstract

Introduction: The corticobasal syndrome (CBS) is associated with several neuropathologic disorders, including corticobasal degeneration and Alzheimer's disease (AD).

Method: In this report, we studied 43 AD patients with CBS (AD-CBS) and compared them with 42 AD patients with typical amnestic syndrome (AD-AS), as well as 15 cases of corticobasal degeneration and CBS pathology.

Results: Unlike AD-AS, AD-CBS had prominent motor problems, including limb apraxia (90%), myoclonus (81%), and gait disorders (70%). Alien limb phenomenon was reported in 26% and cortical sensory loss in 14%. Language problems were also more frequent in AD-CBS, and memory impairment was less frequent. AD-CBS had more tau pathology in perirolandic cortices but less in superior temporal cortex than AD-AS. In addition, AD-CBS had greater neuronal loss in the substantia nigra.

Discussion: AD-CBS is a clinicopathological subtype of AD with an atypical distribution of Alzheimer-type tau pathology. Greater neuronal loss in the substantia nigra may contribute to Parkinsonism which is not a feature of typical AD.

Keywords: Alzheimer's disease; Corticobasal syndrome; Neurodegeneration; Neuropathology; Tau.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors have declared that no conflict of interest exists.

Figures

Fig. 1.
Fig. 1.. Clinical features during the disease course of AD-CBS and controls
Data are displayed as frequency of given clinical feature (percent of total in that group). Post hoc pairwise comparison analysis is performed with Mann-Whitney rank sum test. The asterisks (*) indicate significant differences between AD-CBS and CBD-CBS (myoclonus - P=0.006, aphasia = P=0.007, memory impairment; P=0.004, hallucinations or delusions; P=0.01, dystonia; P=0.04, and falls; P=0.03)
Fig. 2.
Fig. 2.. Macroscopic examples of AD-CBS and AD-AS
Comparison of representative cases of AD-CBS (A, B, C) and AD-AS (D, E, F). The midsagittal view shows marked medial frontal atrophy, especially in paracentral lobule and peri-Rolandic region (MTR) in AD-CBS (A), but not in AD-AS (D). Coronal sections show ventricular enlargement, with disproportionate enlargement of frontal compared with temporal horns of the lateral ventricle in AD-CBS (B) compared with AD-AS (E). Transverse sections of the midbrain show decreased neuromelanin pigment in the lateral substantia nigra (SN) in AD-CBS (C) compared with AD-AS (F).
Fig. 3.
Fig. 3.. Phospho-tau immunohistochemistry of AD-CBS and AD-AS
Peri-Rolandic cortices of representative cases of AD-CBS (A and D) and AD-AS (B and D) immunostained for phospho-tau. Boxed areas of motor cortex in A and B are shown at higher magnification in C and D. Representative higher magnification images of phospho-tau immunostaining in motor cortex of AD-CBS (E) and AD-AS (F) after application of the image analysis color deconvolution algorithm on the same images in (G) and (H). Strong positive pixels are shown in red. Tau burden is the ratio of strong positive pixels to all pixels in the region of interest. The analysis does not discriminate between NFT and neuropil threads. Note higher density of tau pathology in motor cortex of AD-CBS compared with AD-AS. Scale bars: A - 150-μm, C - 20-μm, E - 50-μm.

Similar articles

Cited by

References

    1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. - PubMed
    1. Panegyres PK, Goh J, McCarthy M, Campbell AI. The Nature and Natural History of Posterior Cortical Atrophy Syndrome: A Variant of Early-onset Alzheimer Disease. Alzheimer Dis Assoc Disord. 2017;31:295–306. - PubMed
    1. Josephs KA, Whitwell JL, Duffy JR, Vanvoorst WA, Strand EA, Hu WT, et al. Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology. 2008;70:25–34. - PMC - PubMed
    1. Gorno-Tempini ML, Brambati SM, Ginex V, Ogar J, Dronkers NF, Marcone A, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008;71:1227–34. - PMC - PubMed
    1. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56:1233–9. - PubMed

Publication types